Get the Stockscreener App
0.8285
0.18%
0.0015
Pre-market:
.83
0.0015
+0.18%
Reviva Pharmaceuticals Holdings Inc stock is traded at $0.8285, with a volume of 527.92K.
It is up +0.18% in the last 24 hours and down -81.21% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$0.827
Open:
$0.851
24h Volume:
527.92K
Relative Volume:
1.16
Market Cap:
$10.54M
Revenue:
-
Net Income/Loss:
$-22.76M
P/E Ratio:
-0.0903
EPS:
-9.1712
Net Cash Flow:
$-27.90M
1W Performance:
-55.70%
1M Performance:
-81.21%
6M Performance:
-85.96%
1Y Performance:
-96.33%
1-Day Range:
$0.8004
$0.851
1-Week Range:
$0.6697
$0.9435
52-Week Range:
$0.6697
$23.40
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.8285 | 10.54M | 0 | -22.76M | -27.90M | -9.1712 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split - Insider Monkey
CVI/Heights disclose 666,667 shares (5.2%) in Reviva Pharmaceuticals (NASDAQ: RVPH) - Stock Titan
Aug Mood: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant stock outperform in a bear marketWeekly Stock Analysis & Safe Investment Capital Preservation Plans - baoquankhu1.vn
If You Invested $1,000 in Reviva Pharmaceutcls Hldgs Inc (RVPH) - Stock Titan
Parag Saxena reports Reviva (RVPH) stake at 2.8%, below 5% level - Stock Titan
Reviva Pharmaceuticals raises $10 million in public offering By Investing.com - Investing.com Canada
Reviva Pharmaceuticals raises $10 million in public offering - Investing.com
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering - The Manila Times
Reviva says $10M raise funds schizophrenia trial into Q1 2027 - Stock Titan
What's behind the drop in Reviva Pharmaceuticals stock? - MSN
Aug Levels: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant benefit from deglobalization2026 Spike Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Wall Street Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart moneyM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Announces $10 Million Equity Offering - The Globe and Mail
Reviva (NASDAQ: RVPH) CFO granted 40,925 stock options under 2020 plan - Stock Titan
Reviva (RVPH) CEO receives 150,075 stock option grants under 2020 plan - Stock Titan
Reviva Pharmaceuticals Holdings Announces Securities Purchase Agreement and New Warrants Offering March 2026 - Minichart
Reviva Pharmaceuticals (NASDAQ: RVPH) raises equity with detachable warrants and pre‑funded options - Stock Titan
Reviva (NASDAQ: RVPH) prices $10M equity deal to fund Phase 3 trial - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
What's Behind The Drop In Reviva Pharmaceuticals Stock? - Benzinga
Dow Falls Over 300 Points; US Initial Jobless Claims Fall - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
$10M raise backs Reviva's Phase 3 schizophrenia drug trial - Stock Titan
Gold Tumbles Over 6%; Accenture Earnings Top Views - Sahm
Reviva Pharmaceuticals prices $10M public offering at $1.50 By Investing.com - Investing.com India
Reviva Pharmaceuticals announces public stock and warrant offering By Investing.com - Investing.com South Africa
Why Did RVPH Stock Crash 40% In Pre-Market Today? - Stocktwits
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering - GlobeNewswire
Reviva Pharmaceuticals prices $10M public offering at $1.50 - Investing.com
Reviva Pharmaceuticals announces pricing of $10 million public offering at $1.50 per share - marketscreener.com
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering - Benzinga
Reviva Pharmaceuticals announces public stock and warrant offering - Investing.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Reviva Pharmaceuticals (NASDAQ: RVPH) proposes sale of stock, warrants to fund Phase 3 - Stock Titan
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - GlobeNewswire
Press Release: Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - Moomoo
Gainers Report: Is now the right time to enter Reviva Pharmaceuticals Holdings IncQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Setup Watch: Should I hold or sell Conduit Pharmaceuticals Inc now2026 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Value Recap: What makes Reviva Pharmaceuticals Holdings Inc stock attractive todayGDP Growth & AI Based Trade Execution Alerts - baoquankhu1.vn
Breakout Watch: How correlated is Reviva Pharmaceuticals Holdings Inc to the S P5002026 Rallies & AI Enhanced Execution Alerts - baoquankhu1.vn
Volume Summary: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant a good ESG investmentInflation Watch & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Reviva Pharmaceuticals to implement 1-for-20 reverse stock split on March 9 - Investing.com Nigeria
D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals Holdings Inc NPV Share Price - Hargreaves Lansdown
Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears - TechStock²
HC Wainwright & Co. Maintains Reviva Pharmaceuticals Holdings (RVPH) Buy Recommendation - MSN
US Market Wrap: Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant announce a stock splitPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Reviva Pharmaceuticals Announces Major Share Consolidation Plan - AD HOC NEWS
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock reacts to inflationary pressures2025 Pullback Review & Weekly High Potential Stock Alerts - Naître et grandir
CEO Moves: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2025 Market WrapUp & Risk Controlled Swing Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):